Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review

Male breast cancer (MBC) is uncommon in clinical practice. Using the 21-gene assay to facilitate decision-making on comprehensive treatment of MBC is rarely reported. This study reports the case of a 53-year-old man with left breast cancer. Modified radical mastectomy was performed. Endocrine treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Ang, Zhang, Lin, Ji, Ziyao, Fan, Lijuan, Jin, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509981/
https://www.ncbi.nlm.nih.gov/pubmed/31068065
http://dx.doi.org/10.1177/1557988319847856
Descripción
Sumario:Male breast cancer (MBC) is uncommon in clinical practice. Using the 21-gene assay to facilitate decision-making on comprehensive treatment of MBC is rarely reported. This study reports the case of a 53-year-old man with left breast cancer. Modified radical mastectomy was performed. Endocrine treatment was chosen for the patient according to the result of the 21-gene assay, a recommended genomic test of breast cancer. The patient remained in good health without evidence of recurrence at 18-month follow-up. This case provides a reference mode for the comprehensive management of early-stage, estrogen receptor–expressing and lymph node–negative MBC patients.

Ejemplares similares